The data suggests that the incidence and exacerbation of ILD in the Tocilizumab and Rituximab groups may be exaggerated by treatment resistance or by the severity of the disease, since the first line of biologics were anti-TNF agents in most patients [47]. Here, TNF is linked to interstitial lung disease.